Skip to Content
Merck
  • Novel flexible vesicles based topical formulation of levocetirizine: in vivo evaluation using oxazolone-induced atopic dermatitis in murine model.

Novel flexible vesicles based topical formulation of levocetirizine: in vivo evaluation using oxazolone-induced atopic dermatitis in murine model.

Journal of liposome research (2014-03-22)
Shishu Goindi, Gautam Kumar, Amanpreet Kaur
ABSTRACT

Levocetirizine, an active enantiomer of cetirizine is third generation antihistaminic agent used for treating various allergies like atopic dermatitis, chronic idiopathic urticaria and allergic rhinitis. Development of novel topical formulation of levocetirizine based on flexible vesicles (FVs) with an aim to have targeted peripheral antihistaminic effect. The FVs were prepared by thin film hydration method and characterized for drug content, entrapment efficiency, pH, vesicular size, spreadability, morphological characteristics and drug leakage studies. Franz diffusion cell assembly was used to carry out the ex vivo permeation studies through mice skin and the permeation profile of the developed FV formulation was compared with conventional formulations of levocetirizine. The ex vivo permeation studies revealed 1.78-fold increase in percent permeation of levocetirizine from FV formulation as compared to conventional formulations of levocetirizine in 8 h. Further, oxazolone induced atopic dermatitis murine model was selected to study the in vivo pharmacodynamic activity. The developed formulation was evaluated for scratching score, erythema score and histological evaluation. There was marked reduction in scratching score from 15.25 scratches/20 min with conventional levocetirizine cream to 6.75 scratches/20 min with application of levocetirizine FV formulation. Also, there was significant reduction in erythema score as well as dermal eosinophil count. Results of skin sensitivity and toxicity studies suggest that the developed formulation was dermally safe and nontoxic. A novel FVs based topical formulation of levocetirizine was successfully developed for treatment of atopic dermatitis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Octadecylamine, ≥99% (GC)
Sigma-Aldrich
1-Hexadecanol, 95%
Sigma-Aldrich
1-Hexadecanol, ≥99%
Sigma-Aldrich
Octadecylamine, technical grade, 90%
Sigma-Aldrich
Octadecylamine, ≥99.0% (GC)
Sigma-Aldrich
1-Hexadecanol, ReagentPlus®, 99%
Trolamine, European Pharmacopoeia (EP) Reference Standard
Supelco
Triethanolamine, analytical standard
Supelco
Cetyl Alcohol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Sodium deoxycholate, BioXtra, ≥98.0% (dry matter, NT)
Sigma-Aldrich
Triethanolamine, BioUltra, ≥99.5% (GC)
Sigma-Aldrich
Sodium deoxycholate, ≥97% (titration)
USP
Cetyl alcohol, United States Pharmacopeia (USP) Reference Standard
SAFC
Sodium deoxycholate
Sigma-Aldrich
Triethanolamine, ≥99.0% (GC)
Supelco
Cetyl alcohol, analytical standard
Sigma-Aldrich
Triethanolamine, puriss., meets analytical specification of NF, ≥99% (GC)
Sigma-Aldrich
Triethanolamine, reagent grade, 98%
Sigma-Aldrich
Triethanolamine, puriss. p.a., ≥99% (GC)
Cetyl alcohol, European Pharmacopoeia (EP) Reference Standard